Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain

NCT06596681 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT06596681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06596681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
September 11, 2024
Completion date
December 31, 2026
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pain, intractable